PTPRQ

Across TCGA pan-cancer cohorts, PTPRQ Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PTPRQ data layer compared with 18 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher PTPRQ Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PTPRQ expression acts as an unfavorable survival marker.

KIRC, CESC, and ESCA are the cancer types where PTPRQ Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.054	0.881	<.001	30	view →
CESC	OS	Median	III,IV	0.185	0.667	.009	12	view →
ESCA	DFS	Median	III,IV	0.080	0.442	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	All	0.267	0.688	.001	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PTPRQ–KIRC (OS)

Open the KIRC breakdown →